Compass Therapeutics/$CMPX
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Ticker
$CMPX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
35
ISIN
US20454B1044
Website
CMPX Metrics
BasicAdvanced
$329M
-
-$0.40
1.19
-
Price and volume
Market cap
$329M
Beta
1.19
52-week high
$4.08
52-week low
$0.77
Average daily volume
845K
Financial strength
Current ratio
8.332
Quick ratio
7.559
Long term debt to equity
5.687
Total debt to equity
5.786
Profitability
EBITDA (TTM)
-61.246
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-6,496.59%
Operating margin (TTM)
-7,273.06%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-26.41%
Return on equity (TTM)
-41.31%
Valuation
Price to revenue (TTM)
385.863
Price to book
2.98
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-7.413
Free cash flow yield (TTM)
-13.49%
Free cash flow per share (TTM)
-32.10%
Growth
Earnings per share change (TTM)
14.28%
3-year earnings per share growth (CAGR)
-28.33%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
Bulls say / Bears say
Compass Therapeutics has received multiple 'buy' ratings from analysts, including a recent upgrade to 'strong-buy' by Leerink Partners with a price target of $6.00, indicating strong confidence in the company's growth prospects. (marketbeat.com)
The company's lead product candidate, CTX-009, is advancing in clinical trials, with the completion of enrollment for the COMPANION-002 biliary tract cancer trial, suggesting potential for positive outcomes. (markets.businessinsider.com)
Compass Therapeutics maintains a solid financial position, with sufficient cash reserves projected to fund operations into the first quarter of 2027, providing stability for ongoing research and development. (markets.businessinsider.com)
The Phase 2 COMPANION-003 trial's monotherapy component for CTX-009 in advanced colorectal cancer did not meet expected outcomes, raising concerns about the efficacy of this treatment approach. (markets.businessinsider.com)
The discontinuation of the CTX-471 + pembrolizumab trial due to safety concerns narrows the company's pipeline and may impact future growth prospects. (markets.businessinsider.com)
Leerink Partners downgraded Compass Therapeutics from 'outperform' to 'market perform' with a reduced price target of $4.00, reflecting tempered expectations for the company's near-term performance. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
CMPX News
AllArticlesVideos
Compass Therapeutics to Participate in Upcoming May Investor Events
GlobeNewsWire·2 months ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·2 months ago
2 Penny stocks to buy in May 2025
Finbold·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $329M as of June 20, 2025.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of June 20, 2025.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
